Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Pharmaceuticals (NASDAQ: LXRX) entered a loan facility with Hercules Capital providing up to $100 million in borrowing capacity, with an initial $55 million funded at closing to repay an existing facility.

Rhea-AI Summary

Lexicon Pharmaceuticals (NASDAQ: LXRX) entered a loan facility with Hercules Capital providing up to $100 million in borrowing capacity, with an initial $55 million funded at closing to repay an existing facility. The facility includes two optional tranches of $20 million and $25 million, a floating rate (prime +3.1%, floor 9.85%), an 18-month interest-only period (two six-month extension options), and maturity by May 4, 2030. Obligations are secured by a first lien on assets and include customary covenants and a minimum cash covenant effective June 1, 2027.

Positive

• Initial $55 million funded at closing
• Up to $100 million total borrowing capacity
• Interest-only period of 18 months with extensions
• Maturity extended to May 4, 2030
• Non-dilutive capital supporting late-stage programs

Negative

• Loans secured by first lien on all assets
• Floating rate with a 9.85% floor may raise interest cost
• Minimum cash covenant effective June 1, 2027

Argus May 5 session

+3.12% close to close Open Argus

Details

News Market Reaction – LXRX

In the May 5 session, LXRX gained 3.12%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a new loan facility providing up to $100 million in non-dilutive borrowing...

Analysis

This announcement details a new loan facility providing up to $100 million in non-dilutive borrowing capacity, with $55 million funded at closing to refinance prior debt. Key features include a floating rate of prime plus 3.1% with a 9.85% floor, an initial 18-month interest-only period, and maturity in 2030. Investors may focus on how this added flexibility supports upcoming clinical and regulatory milestones, as well as adherence to covenants such as the minimum cash requirement starting in 2027.

Key Figures

Loan facility capacity: $100 million Initial funding: $55 million Second tranche: $20 million +5 more

Loan facility capacity

$100 million

Total borrowing capacity under Hercules Capital agreement

Initial funding

$55 million

Funded at closing to repay Oxford Finance loan facility

Second tranche

$20 million

Available at Lexicon’s option upon meeting specified milestones

Third tranche

$25 million

Available after second tranche draw, subject to Hercules’ consent

Interest rate spread

Prime rate + 3.1%

Floating rate on loan facility, with defined floor

Interest rate floor

9.85%

Minimum interest rate on the Hercules loan facility

Interest-only period

18 months

Initial period, with potential for two six-month extensions

Loan maturity date

May 4, 2030

Final maturity when principal and accrued interest are due

Historical Context

5 past events · Latest: Apr 30

5 events

1. Apr 30

   Earnings call scheduling

   24h Move

   +3.9%

   Announcement of Q1 2026 results date and related conference call details.

2. Apr 17

   Clinical data presentation

   24h Move

   +1.6%

   Phase 2b and preclinical data at AAN supporting pilavapadin Phase 3 dose.

3. Mar 24

   Cardiology data update

   24h Move

   +4.9%

   Multiple ACC presentations on sotagliflozin efficacy and quality-of-life data.

4. Mar 23

   Clinical trial initiation

   24h Move

   +5.1%

   Start of Phase 1 LX9851 obesity study under Novo Nordisk collaboration.

5. Mar 11

   Diabetes data presentation

   24h Move

   +3.6%

   Post hoc sotagliflozin data at ATTD and planned NDA resubmission for ZYNQUISTA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

loan facility, non-dilutive capital, prime rate, interest-only period, +4 more

8 terms

loan facility financial

"entered into a loan facility with Hercules Capital, Inc."

A loan facility is a formal agreement with a bank or lender that lets a company borrow money up to a set limit under agreed terms — like a large credit card or mortgage tailored for a business. It matters to investors because it determines how easily a company can get cash for operations, growth or debt repayment, and influences interest costs, leverage and any lender-imposed rules that can affect future strategy and risk.

non-dilutive capital financial

"Access to this non-dilutive capital provides Lexicon with greater financial flexibility"

Funding that does not require a company to issue new shares or reduce existing owners’ percentage of ownership, such as grants, certain loans, licensing deals, or customer prepayments. It matters to investors because it preserves each shareholder’s stake and per-share value—like getting a loan or a gift instead of selling part of the company—while still carrying obligations (repayment, milestones, or restrictions) that can affect future cash flow and growth.

prime rate financial

"carries a floating interest rate equal to the prime rate plus 3.1%"

The prime rate is the interest rate banks typically charge their most creditworthy customers for short-term loans and serves as a common baseline for many other interest rates. Think of it as a price tag for borrowing: when the prime rate rises, costs for business loans, mortgages and consumer credit usually go up, which can slow spending, squeeze profits and influence stock prices and interest-sensitive sectors.

interest-only period financial

"provides for an initial interest-only period of 18 months"

A period during a loan when the borrower pays only the interest charges and none of the original principal, so monthly payments are lower but the loan balance does not shrink. For investors, this affects cash flow and risk: borrowers may have higher near-term liquidity but face larger payments or refinancing later, which can influence a company’s ability to pay dividends, meet obligations, or require new financing — similar to paying rent on borrowed money before starting to pay it down.

maturity date financial

"extended interest-only period and maturity date and the opportunity"

The maturity date is the specific day when a loan, bond, or investment reaches its full term and the borrower must repay the borrowed amount in full. It is important for investors because it indicates when they will receive their initial money back and can plan their future financial steps accordingly. Think of it as the due date for a loan or the day a gift card or coupon expires.

View in glossary

first lien security interest financial

"secured by a first lien security interest in all of Lexicon’s assets"

A first lien security interest is a lender's legally enforceable right to specific assets of a borrower that gives that lender the top-priority claim if the borrower defaults. For investors, that priority matters because it generally increases the chance of recovering funds, lowers credit risk and often translates into lower borrowing costs compared with lower-ranked claims—like being first in line at a repayment counter rather than behind other creditors.

covenants financial

"subject to customary covenants, including a minimum cash covenant"

Covenants are rules written into loan or bond contracts that require a company to do or avoid certain things—like keeping debt below a set level or not selling key assets. They matter to investors because they protect lenders and influence a company’s flexibility: tight covenants can limit growth plans but lower default risk, while loose covenants give freedom but increase credit risk, similar to how household rules affect a family’s budget choices.

minimum cash covenant financial

"including a minimum cash covenant beginning on June 1, 2027"

A minimum cash covenant is a loan agreement clause that requires a company to keep at least a specified amount of cash or liquid assets on hand, like a bank requiring you to maintain a minimum balance. It matters to investors because it limits how management can spend or return cash, reduces the risk of surprise default by ensuring a short-term safety buffer, and can signal lender concern about the company’s liquidity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

$55 million funded at closing to repay existing loan facility

THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC) that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones.

“Operational excellence, financial discipline and financial flexibility are key pillars of our corporate strategy for long-term growth,” said Scott Coiante, Lexicon’s chief financial officer. “By refinancing our existing loan facility with Hercules Capital, a strong partner with a history of supporting biotech innovation, we are expanding our access to non-dilutive capital and gaining additional flexibility to opportunistically deploy capital on value-creating initiatives, including the advancement of our pipeline of late-stage cardiometabolic programs.”

“Hercules Capital is pleased to support Lexicon Pharmaceuticals with a flexible financing solution that will support it through upcoming clinical and regulatory milestones,” said Adam Soller, Managing Director. “This partnership underscores our commitment to funding innovative therapies that address significant unmet medical needs.”

Under the terms of the agreement, the initial $55 million tranche was funded at closing and will be used to repay Lexicon’s existing loan facility with Oxford Finance. The second $20 million tranche is available for draw at Lexicon’s option subject to the achievement of certain clinical, regulatory and financial milestones and specified timing requirements. The third $25 million tranche is available for draw at Lexicon’s option following its draw of the second tranche and subject to Hercules’ consent and specified timing requirements.

The loan facility carries a floating interest rate equal to the prime rate plus 3.1%, with a floor not less than 9.85%. The loan facility provides for an initial interest-only period of 18 months, with the potential for two six-month extensions. The outstanding principal amount and all accrued but unpaid interest shall be repaid on or before May 4, 2030.

Lexicon’s obligations under the loan facility are secured by a first lien security interest in all of Lexicon’s assets and are subject to customary covenants, including a minimum cash covenant beginning on June 1, 2027, subject to extension upon the achievement of certain clinical and financial milestones and waiver upon the achievement of certain financial conditions.

About Lexicon Pharmaceuticals 
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. 

For Media Inquiries:

Dave Belian
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

For Investor Inquiries:

Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key terms of the Hercules loan facility for LXRX?

The facility provides up to $100 million, with $55 million funded at closing. According to the company, optional tranches of $20 million and $25 million, a floating rate (prime +3.1%, floor 9.85%), and maturity on May 4, 2030.

How will the initial $55 million draw affect Lexicon's existing debt?

The $55 million funded at closing repays Lexicon's prior loan facility. According to the company, proceeds were used to retire the Oxford Finance loan and consolidate financing under the Hercules facility for greater flexibility.

What are the interest and repayment features of the LXRX loan with Hercules?

The loan carries a floating rate equal to prime plus 3.1% with a floor of 9.85%. According to the company, there is an 18-month initial interest-only period, potential two six-month extensions, and full repayment due by May 4, 2030.

Under what conditions can Lexicon draw the second and third tranches of the $100M facility?

The second $20 million tranche is optional and conditional on clinical, regulatory, and financial milestones; the third $25 million requires draw of tranche two and Hercules consent. According to the company, timing and milestones are specified in the agreement.

What covenants secure the Hercules loan for LXRX and when do they start?

Lexicon's obligations are secured by a first lien on all assets and include customary covenants. According to the company, a minimum cash covenant begins on June 1, 2027, subject to possible extension or waiver upon certain milestones or conditions.